Stomach Cancer Diagnosis and Staging

Utilizing advanced endoscopy, high resolution CT, and molecular staging to accurately map gastric tumors for precise treatment

Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Diagnosis and Staging of Stomach Cancer

Diagnosis and Staging are the critical first steps in managing stomach cancer, determining the disease’s extent and informing the most effective treatment plan. At Liv Hospital, an internationally accredited center, our multidisciplinary team combines state‑of‑the‑art technology with expert clinical judgment to provide precise, patient‑centered care. Each year, stomach cancer accounts for over 1 million new cases worldwide, and early, accurate assessment dramatically improves survival odds. This page guides patients and caregivers through the comprehensive pathway—from initial clinical evaluation to the final staging report—ensuring transparency and confidence in every decision.

International patients choosing Liv Hospital benefit from coordinated services that include medical translation, travel logistics, and comfortable accommodation, allowing them to focus solely on health outcomes. Below, we detail each component of the diagnostic and staging process, highlighting the tools, procedures, and collaborative steps that define our approach.

Initial Clinical Evaluation and Risk Assessment

The journey begins with a thorough clinical interview and physical examination. Our gastroenterology specialists collect detailed medical histories, focusing on symptoms such as persistent indigestion, unexplained weight loss, or gastrointestinal bleeding. A risk‑assessment questionnaire also captures lifestyle factors, family history of malignancy, and prior Helicobacter pylori infection, which is a known contributor to gastric neoplasia.

Key elements of the initial evaluation include:

Comprehensive symptom review and duration
Physical examination targeting abdominal tenderness or palpable masses
Laboratory tests: complete blood count, liver function, and tumor markers (CEA, CA 19‑9)
Assessment of nutritional status and performance‑status scales (e.g., ECOG)

Based on these findings, patients are stratified into low, intermediate, or high suspicion categories, which dictate the urgency and type of subsequent investigations. This systematic approach minimizes unnecessary procedures while ensuring high‑risk individuals receive prompt, targeted diagnostics.

Imaging Techniques for Precise Diagnosis

Modern imaging is indispensable for visualizing the stomach’s anatomy and detecting metastatic spread. Liv Hospital employs a tiered imaging protocol, beginning with non‑invasive studies and escalating to high‑resolution modalities when indicated.

Common imaging modalities include:

Modality	Purpose	Key Advantages
Upper Gastrointestinal (UGI) Barium Study	Initial structural assessment	Cost‑effective, identifies ulcerations
Contrast‑Enhanced Computed Tomography (CT)	Local tumor extent and distant metastasis	Rapid, 3‑D reconstruction
Magnetic Resonance Imaging (MRI)	Soft‑tissue contrast, liver lesions	No ionizing radiation
Positron Emission Tomography–CT (PET‑CT)	Metabolic activity, occult metastases	High sensitivity for distant disease
Endoscopic Ultrasound (EUS)	Layer‑by‑layer tumor depth assessment	Guides fine‑needle aspiration

Each imaging study contributes specific data that feed into the overall diagnosis and staging algorithm, allowing our oncologists to map the tumor’s size, location, and spread with confidence.

Endoscopic Examination and Biopsy Procedures

Endoscopy remains the gold standard for direct visualization and tissue acquisition. During an upper endoscopy (esophagogastroduodenoscopy, EGD), a high‑definition camera inspects the gastric mucosa, identifies suspicious lesions, and obtains targeted biopsies.

Key steps in the endoscopic workflow:

Preparation: fasting for 6–8 hours; sedation administered by an anesthesiologist
Systematic inspection of the esophagus, stomach, and duodenum
Documentation of lesion size, morphology, and exact location (using the Sydney classification)
Acquisition of at least six biopsy samples from each suspicious area to reduce sampling error
Optional endoscopic ultrasound (EUS) for submucosal lesions and lymph‑node assessment

Biopsy specimens are promptly sent to our pathology laboratory, where they undergo histopathological grading (well‑, moderately, or poorly differentiated) and immunohistochemical staining for HER2, PD‑L1, and microsatellite instability (MSI). These molecular insights are integral to personalized therapy decisions, especially when targeted agents or immunotherapy are considered.

Pathology and Molecular Testing in Staging

Accurate pathology is the cornerstone of reliable staging. After fixation, tissue sections are examined under a microscope to confirm adenocarcinoma and determine the grade. Concurrently, molecular profiling provides actionable data:

HER2 overexpression – predicts response to trastuzumab
Microsatellite instability (MSI) – guides immunotherapy eligibility
Programmed death‑ligand 1 (PD‑L1) expression – informs checkpoint inhibitor use
Next‑generation sequencing panels – identify rare mutations (e.g., CDH1, TP53)

The integration of histology with molecular markers refines the stage grouping and influences both curative and palliative treatment pathways. Our multidisciplinary tumor board reviews each case, ensuring that the final report aligns with international guidelines such as the AJCC 8th edition.

Staging Systems: TNM Classification and Its Application

The Tumor‑Node‑Metastasis (TNM) system remains the universal language for cancer staging. For stomach cancer, the classification captures tumor depth (T), regional lymph‑node involvement (N), and distant metastasis (M). Below is a concise overview used at Liv Hospital:

Category	Description	Stage Group
T1	Tumor invades lamina propria or submucosa	IA
T2	Tumor invades muscularis propria	IB
T3	Tumor penetrates subserosa	IIA
T4a	Tumor invades serosa (visceral peritoneum)	IIB
T4b	Tumor invades adjacent structures	IIIC
N0	No regional lymph‑node metastasis	Varies by T
N1‑N3	1–2, 3–6, ≥7 positive nodes respectively	Higher stage groups
M0	No distant metastasis	Stage I‑III
M1	Distant metastasis present	Stage IV

Accurate assignment of each component relies on the combined data from imaging, endoscopy, and pathology. The final stage not only predicts prognosis but also dictates whether curative surgery, neoadjuvant therapy, or palliative care is appropriate.

Multidisciplinary Planning and Treatment Pathways

Once diagnosis and staging are complete, a personalized treatment plan is crafted by a tumor board comprising surgical oncologists, medical oncologists, radiation oncologists, gastroenterologists, radiologists, and supportive‑care specialists. The board evaluates:

Stage‑specific guidelines (e.g., peri‑operative chemotherapy for stage II‑III)
Patient performance status and comorbidities
Molecular targets identified in pathology
Patient preferences and cultural considerations

Typical pathways include:

Surgery first for early‑stage (IA‑IB) disease
Neoadjuvant chemotherapy or chemoradiotherapy for locally advanced tumors (stage II‑III) to shrink the lesion before resection
Targeted therapy (e.g., trastuzumab) when HER2‑positive
Immunotherapy for MSI‑high or PD‑L1 positive tumors
Palliative systemic therapy and symptom management for stage IV disease

Liv Hospital’s integrated care model ensures seamless transitions between diagnostic phases and therapeutic interventions, minimizing delays and optimizing outcomes for international patients.

Why Choose Liv Hospital?

Liv Hospital combines JCI accreditation, cutting‑edge technology, and a dedicated international patient team to deliver world‑class cancer care. Our experts have extensive experience in gastric oncology, and we provide comprehensive support—from visa assistance to multilingual interpreters—so patients can focus solely on recovery. Choosing Liv Hospital means accessing personalized, evidence‑based treatment within a compassionate, culturally sensitive environment.

Ready to start your journey toward accurate diagnosis and tailored treatment? Contact Liv Hospital today to schedule a virtual consultation with our gastric cancer specialists. Let us handle the logistics while you prioritize your health.

Get an Online Consultation with
Certified Doctors

Related Doctors

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Yasemin Altuner Torun

Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Spec. MD. Vildan Kayku

Liv Hospital Bahçeşehir Spec. MD. Vildan Kayku Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Meral Beksaç

Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. Ceyda Aslan

Spec. MD. Ceyda Aslan Hematology

Spec. MD. Elkhan Mammadov

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elmir İsrafilov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Natavan Azizova

Spec. MD. Natavan Azizova Medical Oncology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology

30 Years of Excellence

Trusted Worldwide

With patients from across the globe, we bring over three decades of medical

Reviews from 9,651

4,9

Worth a look

Was this article helpful?

Was this article helpful?

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

FREQUENTLY ASKED QUESTIONS

What are the first steps in diagnosing stomach cancer?

During the initial clinical evaluation, gastroenterology specialists collect a comprehensive medical history focusing on persistent indigestion, weight loss, and gastrointestinal bleeding. A physical examination looks for abdominal tenderness or palpable masses. Laboratory tests such as CBC, liver function, and tumor markers (CEA, CA 19‑9) are ordered, and nutritional status is assessed using scales like ECOG. Based on these findings, patients are stratified into low, intermediate, or high suspicion categories, which determines the urgency of further imaging or endoscopic investigations. This systematic approach minimizes unnecessary procedures while ensuring high‑risk patients receive prompt, targeted diagnostics.

Which imaging modalities are used to stage gastric cancer?

The imaging protocol starts with a non‑invasive Upper Gastrointestinal (UGI) barium study to identify structural abnormalities. If further detail is needed, a contrast‑enhanced CT scan provides rapid 3‑D visualization of local tumor depth and distant spread. MRI offers superior soft‑tissue contrast, especially for liver lesions, without ionizing radiation. PET‑CT adds metabolic information, detecting occult metastases with high sensitivity. Endoscopic ultrasound (EUS) delivers layer‑by‑layer assessment of tumor depth and guides fine‑needle aspiration of suspicious lymph nodes. Each modality contributes specific data that feed into the overall staging algorithm.

How does endoscopic ultrasound help in stomach cancer staging?

During an upper endoscopy, a high‑definition camera inspects the gastric mucosa, and if a lesion is found, an endoscopic ultrasound probe is introduced. EUS provides real‑time, high‑resolution images of the gastric wall layers, enabling clinicians to determine whether the tumor is confined to the mucosa, submucosa, muscularis, or has penetrated the serosa. Additionally, EUS can target regional lymph nodes for fine‑needle aspiration, yielding cytology that confirms nodal involvement. This information refines the N component of the TNM classification, influencing decisions about neoadjuvant therapy versus upfront surgery.

What treatment options are considered based on the stage of stomach cancer?

For stage IA‑IB tumors, curative gastrectomy with adequate lymph‑node dissection is standard. Stages II‑III typically receive peri‑operative chemotherapy or chemoradiotherapy to shrink the tumor before resection, improving resectability and survival. If HER2 is overexpressed, trastuzumab is incorporated into the regimen. MSI‑high or PD‑L1‑positive tumors may be treated with checkpoint inhibitors, either alone or in combination with chemotherapy. Stage IV disease, characterized by distant metastasis (M1), is managed with systemic chemotherapy, targeted agents, or immunotherapy to control disease and alleviate symptoms. Palliative radiotherapy and supportive care are added as needed.

How does Liv Hospital support international patients during diagnosis and staging?

International patients benefit from a coordinated service that includes multilingual interpreters, assistance with visa applications, and organized travel arrangements. The hospital offers comfortable lodging close to the treatment center, reducing the stress of navigating an unfamiliar environment. A dedicated international patient coordinator ensures that all appointments—clinical evaluation, imaging, endoscopy, and pathology—are scheduled efficiently, minimizing wait times. This comprehensive support allows patients to focus on their health while the hospital handles logistical and administrative details.

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

Start Chat on WhatsApp or call us at +90 530 174 28 17